|
1
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sano D and Myers JN: Metastasis of
squamous cell carcinoma of the oral tongue. Cancer Metast Rev.
26:645–662. 2007. View Article : Google Scholar
|
|
3
|
Guerrero-Preston R, Soudry E, Acero J,
Orera M, Moreno-López L, Macía-Colón G, Jaffe A, Berdasco M,
Ili-Gangas C, Brebi-Mieville P, et al: NID2 and HOXA9 promoter
hypermethylation as biomarkers for prevention and early detection
in oral cavity squamous cell carcinoma tissues and saliva. Cancer
Prev Res (Phila). 4:1061–1072. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rasch MG, Lund IK, Almasi CE and
Hoyer-Hansen G: Intact and cleaved uPAR forms: Diagnostic and
prognostic value in cancer. Front Biosci. 13:6752–6762. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee EJ, Whang JH, Jeon NK and Kim J: The
epidermal growth factor receptor tyrosine kinase inhibitor ZD1839
(Iressa) suppresses proliferation and invasion of human oral
squamous carcinoma cells via p53 independent and MMP, uPAR
dependent mechanism. Ann N Y Acad Sci. 1095:113–128. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jing Y, Bejarano MT, Kovacs K and Merchan
J: Abstract 3545: Stromal selective targeting by uPAR retargeted
oncolytic measles virus inhibits breast cancer progression. Cancer
Res. 75 15 Suppl:Abstract nr 3545. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gao N, Bozeman E, Qian W, Staley C, Wang
A, Mao H and Yang L: Abstract 4593: Targeted therapy of pancreatic
cancer by intraperitoneal delivery of uPAR-targeted theranostic
nanoparticles. Cancer Res. 74 19 Suppl:Abstract nr 4593. 2014.
View Article : Google Scholar
|
|
8
|
Gorantla B, Asuthkar S, Rao JS, Patel J
and Gondi CS: Suppression of the uPAR-uPA system retards
angiogenesis, invasion, and in vivo tumor development in pancreatic
cancer cells. Mol Cancer Res. 9:377–389. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dass K, Ahmad A, Azmi AS, Sarkar SH and
Sarkar FH: Evolving role of uPA/uPAR system in human cancers.
Cancer Treat Rev. 34:122–136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zh XY, Wu JZ, Liu B, et al: Establishment
and characterization of a metastatic cell line from spinal cord
metastasis induced by injection of tongue cancer Tb cells in nude
mouse. J Chin Stomatol. 18:412–415. 2002.(In Chinese).
|
|
11
|
Wang J, Chen J, Ma M, et al: Construction
and identification of specific shRNA interference plasmid vector
targeted to uPAR gene. Chin Oncol. 19:904–909. 2009.(In
Chinese).
|
|
12
|
Wu YM, Zhang XN, Han ZY, Li CY and Chen
NC: Construction of shRNA expression vector pWH1 and its function
in silencing the HIF1 gene. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
24:115–118. 2008.(In Chinese). PubMed/NCBI
|
|
13
|
Lærum OD, Ovrebo K, Skarstein A,
Christensen IJ, Alpízar-Alpízar W, Helgeland L, Danø K, Nielsen BS
and Illemann M: Prognosis in adenocarcinomas of lower oesophagus,
gastro-oesophageal junction and cardia evaluated by
uPAR-immunohistochemistry. Int J Cancer. 131:558–569. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boonstra MC, Verspaget HW, Ganesh S,
Kubben FJ, Vahrmeijer AL, van de Velde CJ, Kuppen PJ, Quax PH and
Sier CF: Clinical applications of the urokinase receptor (uPAR) for
cancer patients. Curr Pharm Des. 17:1890–1910. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mahmood T and Yang PC: Western blot:
Technique, theory, and trouble shooting. N Am J Med Sci. 4:429–434.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brown GT and Murray GI: Current
mechanistic insights into the roles of matrix metalloproteinases in
tumour invasion and metastasis. J Pathol. 237:273–281. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pavón MA, Arroyo-Solera I, Céspedes MV,
Casanova I, León X and Mangues R: uPA/uPAR and SERPINE1 in head and
neck cancer: Role in tumor resistance, metastasis, prognosis and
therapy. Oncotarget. 7:57351–57366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Noh H, Hong S and Huang S: Role of
urokinase receptor in tumor progression and development.
Theranostics. 3:487–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Almholt K, Lærum OD, Nielsen BS, Lund IK,
Lund LR, Rømer J and Jögi A: Spontaneous lung and lymph node
metastasis in transgenic breast cancer is independent of the
urokinase receptor uPAR. Clin Exp Metastasis. 32:543–554. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Margheri F, Luciani C, Taddei ML, Giannoni
E, Laurenzana A, Biagioni A, Chillà A, Chiarugi P, Fibbi G and Del
Rosso M: The receptor for urokinase-plasminogen activator (uPAR)
controls plasticity of cancer cell movement in mesenchymal and
amoeboid migration style. Oncotarget. 5:1538–1553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu J, Muller KA, Furnari FB, Cavenee WK,
VandenBerg SR and Gonias SL: Neutralizing the EGF receptor in
glioblastoma cells stimulates cell migration by activating
uPAR-initiated cell signaling. Oncogene. 34:4078–4088. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Randle DD, Clarke S, Henderson V and
Odero-Marah VA: Snail mediates invasion through uPA/uPAR and the
MAPK signaling pathway in prostate cancer cells. Oncol Lett.
6:1767–1773. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kotipatruni RR, Nalla AK, Asuthkar S,
Gondi CS, Dinh DH and Rao JS: Apoptosis induced by knockdown of
uPAR and MMP-9 is mediated by inactivation of EGFR/STAT3 signaling
in medulloblastoma. PLoS One. 7:e447982012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang L and Han X: The urokinase
plasminogen activator system in breast cancer invasion and
metastasis. Biomed Pharmacother. 67:179–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang WG, Sanders AJ, Katoh M, Ungefroren
H, Gieseler F, Prince M, Thompson SK, Zollo M, Spano D, Dhawan P,
et al: Tissue invasion and metastasis: Molecular, biological and
clinical perspectives. Semin Cancer Biol. 35 Suppl:S244–S275. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Illemann M, Laerum OD, Hasselby JP,
Thurison T, Høyer-Hansen G and Nielsen HJ: Danish Study Group on
Early Detection of Colorectal Cancer, Christensen IJ:
Urokinase-type plasminogen activator receptor (uPAR) on
tumor-associated macrophages is a marker of poor prognosis in
colorectal cancer. Cancer Med. 3:855–864. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marampon F, Gravina GL, Di Rocco A,
Bonfili P, Di Staso M, Fardella C, Polidoro L, Ciccarelli C,
Festuccia C, Popov VM, et al: MEK/ERK inhibitor U0126 increases the
radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by
downregulating growth and DNA repair signals. Mol Cancer Ther.
10:159–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vara Fresno JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang JY, Zong CS, Xia W, Yamaguchi H, Ding
Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, et al: ERK promotes
tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.
Nat Cell Biol. 10:138–148. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hayashido Y, Kitano H, Sakaue T, Fujii T,
Suematsu M, Sakurai S and Okamoto T: Overexpression of integrin αv
facilitates proliferation and invasion of oral squamous cell
carcinoma cells via MEK/ERK signaling pathway that is activated by
interaction of integrin αvβ8 with type I collagen. Int J Oncol.
45:1875–1882. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yajima I, Kumasaka MY, Thang ND, Goto Y,
Takeda K, Yamanoshita O, Iida M, Ohgami N, Tamura H, Kawamoto Y and
Kato M: RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant
melanoma progression and therapy. Dermatol Res Pract.
2012:3541912012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ebi H, Costa C, Faber AC, Nishtala M,
Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M,
et al: PI3K regulates MEK/ERK signaling in breast cancer via the
Rac-GEF, P-Rex1. Proc Natl Acad Sci USA. 110:21124–21129. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hong SW, Jung KH, Lee HS, Choi MJ, Son MK,
Zheng HM and Hong SS: SB365 inhibits angiogenesis and induces
apoptosis of hepatocellular carcinoma through modulation of
PI3K/Akt/mTOR signaling pathway. Cancer Sci. 103:1929–1937. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gondi CS, Kandhukuri N, Dinh DH, Gujrati M
and Rao JS: Down-regulation of uPAR and uPA activates
caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J
Oncol. 31:19–27. 2007.PubMed/NCBI
|
|
35
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Randle DD, Clarke S and Odero-Marah V:
Abstract 2407: Snail 1 regulates invasion through uPA-uPAR and
MMP-9 signaling in prostate cancer cells. Cancer Res. 72 8
Suppl:Abstract nr 2407. 2012. View Article : Google Scholar
|
|
37
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Oskarsson T, Batlle E and Massagué J:
Metastatic stem cells: Sources, niches, and vital pathways. Cell
Stem Cell. 14:306–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
